The Rand Corp. has issued a perspective titled “The Cost Savings Potential of Biosimilar Drugs in the United States.” It predicts that “biosimilars will lead to a $44.2 billion reduction in direct spending on biologic drugs from 2014 to 2024, or about 4 percent of total biologic spending over the same period, with a range of $13 billion to $66 billion.” The report cautions, however, that actual savings will depend on the specific provisions of the U.S. Food and Drug Administration’s final regulatory framework for the approval of biosimilars, as well as on levels of competition, payment arrangements and acceptability.